Time-dependent Amiodarone Treatment in Atrial Fibrillation

• Status: Completed
• Trial end date: 2009-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Sixty consecutive emergency patients with newly diagnosed Atrial Fibrillation were randomized into two groups. The first received intravenous amiodarone infusions continuously for 24 hours; the second received Amiodarone until sinus rhythms was reached or for up to 72 hours.

The efficacy and safety of administering intravenous infusions of amiodarone for up to 72 hours were investigated and compared to the efficacy and safety of administering a standard 24 hours infusion of amiodarone. Specifically, the use of up to 72 hours infusions was considered as a new strategy to improve rates of conversion to sinus rhythm without altering the safety profile of the drug.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
• Treatments: Amiodarone

Criteria

Inclusion Criteria:

• ≥18 years old

• Emergency patients

• First symptomatic episodes of Atrial Fibrillation

Exclusion Criteria:

• Hemodynamic instability,

• Previous use of antiarrhythmic drugs

• Use of digoxin seven or fewer days prior to the study

• Active thyroid disease

• Known adverse reactions to amiodarone

• Other ventricular arrhythmias

• Contraindications for anticoagulation

• Acute renal failure

• Chronic liver disease

• Transaminase levels that were twice the normal levels

• Acute pulmonary edema

• Uncontrolled hypertension (> 180/110 mmHg)

• Unstable angina

• Patients who were pregnant and/or breast feeding